| T O P I C R E V I E W |
| Heirsolo |
Posted - 06/22/2009 : 19:05:04
PRESIDENT BARACK OBAMA RECEIVES AN OPEN INVITATION REGARDING REAL HEALTH CARE REFORM IN 2009, SPECIAL REFERENCE TO SKIN CANCER
Dear President Obama
I refer to your email regarding real health care reform in 2009.
I strongly agree that the real reform should uphold the three principles -- it must reduce costs, guarantee choice and ensure quality care for every person.
I have an instance, herewith proposed, which will readily meet your three principles, health care costs reductions, guarantee choice and secure quality care of individuals.
THE CURRENT DILEMMA
In 2001 it was reported that in the US Medicare Skin Cancer Costs hit $1.5 Billion. This was derived from a 5% cross section analysis of the 1996 Medicare billing database.
In a 2008 fact sheet for skin cancer from the American Academy of Dermatology, it was noted that in 2004, the total estimated direct costs associated with the treatment of non-melanoma skin cancers in the US was $1.5 Billion. If according to statistics there were 1.2 million new cases in 2004, then the average cost to treat each skin cancer was about $1,250.
The Skin Cancer Foundation says, the skin cancer disease is the number 1 cancer in men over 50 years, ahead of the combined prostate, lung and colon cancers. In the past 30 years, skin cancer incidence has tripled in woman under age 40 years.
An American Cancer Society Pamphlet shows that an estimated 11,200 people will die of skin cancer this year in the US, 8420 from melanoma and 2780 from other non-melanoma skin cancers.
In the US dermatologists treat about 3/4 of non-melanoma skin cancers. General surgeons and plastic and reconstructive surgeons each treat about 10% of the cases. Surprisingly, primary care physicians only treat about 5% of non-melanoma skin cancers.
Destruction, the least expensive treatment modality, was used in half of all cases; 41% of lesions were excised and 8% were removed with Mohs micrographic surgery.
Average Medicare Part B costs, reflecting office-based but not hospital-based treatment of non-melanoma skin cancer, were $244 for diagnosis, $436 for destruction, $779 for excision and repair, $1416 for Mohs micrographic surgery and $2814 for radiation therapy and these costs were back then in 1996.
Thus, we can conclude that the current treatments of non-melanoma skin cancers are strains on the health care system.
THE ANSWER
In an unpresuming manner I firmly believe that there is a system available that will uphold your three principles.
First a brief background of the proposed system.
In 1987 Dr Bill Cham, a Dutch citizen residing in Australia, and his colleagues published an article in a scientific journal describing the anticancer effects of glycoalkaloids.
During that same year Dr Cham and his colleague Dr Heather Meares published further work showing that these glycoalkaloids were effective in the treatment of human skin cancers.
Since then Dr Cham has enbarked in fundamental and clinical research showing conclusively that these glycoalkaloids had great potential for mankind.
Many independent scientists worldwide have confirmed and extended his observations. Although very promising, substantial more research is required before any claims can be made regarding treatment of terminal internal cancers in man using these glycoalkaloids.
However, this is not the case for the treatment of non-melanoma skin cancers with these glycoalkaloids.
Tremendous amounts of pre-clinical and clinical work have shown that a simple cream containing these glycoalkaloids are very effective and safe when treating such skin cancers.
More recently, in 2008, independent dermatologists at ten hospitals in the United Kingdom have published their clinical studies of over two years in the International Journal of Dermatology. They have concluded that the glycoalkaloid cream has overall efficacy, patient acceptance, low incidence of local adverse events and no systemic side-effects.
These observations confirm the research and the publications by Dr Cham during the last two decades.
For further information, including references of some relevent publications, regarding the glycoalkaloid technology please visit www.curadermbec5global.com
Finally, regarding advocating your three principles of real health care reform in 2009.
REDUCE COSTS
The cost for treating non-melanoma skin cancer with a cream containing the glycoalkaloids is only a small fraction when compared with the existing treatments.
GUARANTEE CHOICE
The treatment of non-melanoma skin cancer with the glycoalkaloids in a cream will be a modality in addition to existing treatments.
SECURE QUALITY CARE
The published studies conclusively show the efficacy of the glycoalkaloid cream. Patients acceptance is good, there is low incidence of local adverse events and there is no systemic side effects. In other words this product is very effective and is very safe.
The cosmetic end result of lesions treated with the cream glycoalkaloids is far superior to any other available treatment. To see pictorial examples of various cases please see publications and visit website www.curadermbec5global.com and go to "Clinical Case Studies"
The intrinsic value of a topical cream formulation known as Curaderm BEC5 to safely and effectively treat skin cancer is immense for the public and the financial reward in terms of saving for the country is great, especially under the current world-wide economic downturn. This glycoalkaloid cream is available now.
I hope this information is of interest to you and sincerely hope that you will adopt the the treatment of the glycoalkaloids in a cream formulation for patients suffering with non-melanoma skin cancer.
Please let me know if you require additional information. The above indicated website gives more detailed information.
I look forward to a rapid reply and wish you all the best in establishing a successful health care reform in 2009.
Yours faithfully
TANIA CHASE (personal assistant of Dr Bill Cham)
|
|
|
